EZH2 knockdown in colon (DLD‐1, HT‐29) and breast (HCC‐1806, 4T‐1) cancer cells result in compromised CSC properties in‐vitro (spheroid formation and drug resistance) and in‐vivo (tumorigenic potential) as compared to control cells. The gene discussed is EZH2; the disease is cancer.